Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

1.42
-0.0800-5.33%
Post-market: 1.430.0100+0.70%17:05 EST
Volume:52.95K
Turnover:75.95K
Market Cap:65.12M
PE:-5.82
High:1.54
Open:1.54
Low:1.39
Close:1.50
52wk High:3.22
52wk Low:1.00
Shares:45.86M
Float Shares:28.77M
Volume Ratio:0.16
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2442
EPS(LYR):-0.2534
ROE:-99.43%
ROA:-53.80%
PB:4.27
PE(LYR):-5.60

Loading ...

Entera Bio Director Steven D. Rubin Reports Acquisition of Common Shares

Reuters
·
Yesterday

Entera Bio Board Members Make Open Market Purchases of Company Stock

Reuters
·
Feb 11

Entera Bio Director Steven D. Rubin Acquires Common Shares

Reuters
·
Feb 11

Entera Bio Names Former Pfizer Executive Geno Germano as Chairman

Reuters
·
Feb 09

Entera Bio ernennt Ex-Pfizer-Manager Geno J. Germano zum neuen Aufsichtsratsvorsitzenden

Reuters
·
Feb 09

Entera Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 09

Entera Bio Ltd. Files Initial Statement of Beneficial Ownership for Director Steven D. Rubin

Reuters
·
Feb 06

Steve Rubin Joins Entera Bio Board as Gerry Ostrov Steps Down

Reuters
·
Feb 04

Entera Bio announces expected milestones for Q1 in 2026

TIPRANKS
·
Jan 21

Entera Bio Advances Phase 3 EB613 Osteoporosis Tablet With FDA Protocol Submission Planned for Q1 2026

Reuters
·
Jan 21

Entera Bio CEO Miranda Jayne Toledano Reports Acquisition of Common Shares

Reuters
·
Dec 30, 2025

FDA Qualifies Total Hip BMD as Regulatory Endpoint for Entera Bio's Osteoporosis Drug Development

Reuters
·
Dec 23, 2025

Entera Bio Unveils Oral PTH Tablet Achieving Sustained Calcium Elevation in Preclinical Study

Reuters
·
Dec 22, 2025

Entera Bio Q3 EPS $(0.07) Beats $(0.09) Estimate

Benzinga
·
Nov 15, 2025

Entera Bio reports Q3 net loss of $3.2 million

Reuters
·
Nov 15, 2025

Press Release: Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates

Dow Jones
·
Nov 15, 2025

Entera Bio Ltd expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

Entera Bio presents clinical data from EB613 Phase 2 trial

TIPRANKS
·
Oct 23, 2025

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

GlobeNewswire
·
Oct 16, 2025

Individual investors among Entera Bio Ltd.'s (NASDAQ:ENTX) largest shareholders, saw gain in holdings value after stock jumped 39% last week

Simply Wall St.
·
Oct 11, 2025